Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 12/20 | 0.40 |
| ▸ | SLC5A1 | P13866 | 6/20 | 0.39 |
| ▸ | PYGL | P06737 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4279547 | 1.00 | SLC5A2 (0.40) | SLC5A2SLC5A1PYGL | |
| SCHEMBL20723767 | 1.00 | SLC5A2 (0.40) | SLC5A2SLC5A1PYGL | |
| SCHEMBL20723768 | 1.00 | SLC5A2 (0.40) | SLC5A2SLC5A1PYGL | |
| SCHEMBL27840040 | 0.84 | SLC5A2 (0.45) | SLC5A2SLC5A1 | |
| SCHEMBL27497543 | 0.84 | SLC5A2 (0.45) | SLC5A2SLC5A1 | |
| SCHEMBL30662841 | 0.84 | SLC6A2 (0.46) | SLC5A2 | |
| SCHEMBL29859348 | 0.83 | PYGL (0.47) | SLC5A2SLC5A1PYGL | |
| SCHEMBL9094088 | 0.83 | SLC5A2 (0.40) | SLC5A2SLC5A1PYGL | |
| SCHEMBL8576401 | 0.83 | SLC5A2 (0.40) | SLC5A2SLC5A1PYGL | |
| SCHEMBL20190749 | 0.81 | SLC5A2 (0.55) | SLC5A2SLC5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4585601-A1 | NOVEL OLIGOSACCHARIDE, PRODUCTION INTERMEDIATE FOR NOVEL OLIGOSACCHARIDE, PRODUCTION METHOD FOR NOVEL OLIGOSACCHARIDE, AND PRODUCTION METHOD FOR PRODUCTION INTERMEDIATE FOR NOVEL OLIGOSACCHARIDE | Daiichi Sankyo Company, Limited (JP) | 2025-07-16 | — | — | EP | disclosed |
| US-20220072098-A1 | BOLAAMPHIPHILIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | LAUREN SCIENCES LLC | 2022-03-10 | — | — | US | disclosed |
| US-20190216895-A1 | BOLAAMPHIPHILIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | LAUREN SCIENCES LLC (US) | 2019-07-18 | — | — | US | disclosed |
| US-20160367678-A1 | BOLAAMPHIPHILIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | LAUREN SCIENCES LLC (US) | 2016-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190216895-A1 | BOLAAMPHIPHILIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | GFRA2, GFRA1, NGF | SLC5A2 266/4885SLC5A1 163/4885PYGL 1739/4885 |
| US-20220072098-A1 | BOLAAMPHIPHILIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | GFRA2, GFRA1, NGF | SLC5A2 286/4885SLC5A1 172/4885PYGL 1593/4885 |
| US-20160367678-A1 | BOLAAMPHIPHILIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | GFRA2, GFRA1, NGF | SLC5A2 301/4885SLC5A1 198/4885PYGL 1689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.